Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 11/20 | 0.43 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.36 |
| ▸ | MPO | P05164 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18586099 | 0.83 | SLC9A1 (0.38) | GRM2SLC9A1MPOKMT2AMEN1 | |
| SCHEMBL18586034 | 0.83 | LMNA (0.48) | GRM2SLC9A1KMT2AALDH1A1LMNA | |
| SCHEMBL18616566 | 0.80 | SLC9A1 (0.44) | GRM2SLC9A1MPOKMT2AALDH1A1 | |
| SCHEMBL18586233 | 0.80 | SLC9A1 (0.44) | GRM2SLC9A1MPOKMT2AALDH1A1 | |
| SCHEMBL18585766 | 0.79 | MPO (0.33) | MPO | |
| SCHEMBL18617398 | 0.79 | GRM2 (0.43) | GRM2SLC9A1ALDH1A1LMNATSHR | |
| SCHEMBL18620095 | 0.74 | MPO (0.62) | MPO | |
| SCHEMBL18586454 | 0.74 | HCAR3 (0.39) | GRM2SLC9A1MPOKMT2AALDH1A1 | |
| SCHEMBL18585842 | 0.74 | GRM2 (0.38) | GRM2SLC9A1MPOKMT2AALDH1A1 | |
| SCHEMBL17595750 | 0.74 | GRM2 (0.42) | GRM2SLC9A1MPOALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407422-B2 | Triazolopyridine inhibitors of myeloperoxidase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-10 | — | — | US | disclosed |
| US-20190023701-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL MYERS SQUIBB CO (US) | 2019-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190023701-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | EPX, MPO, SERPINB1 | GRM2 3309/4885SLC9A1 1353/4885MPO 2/4885 |
| US-10407422-B2 | Triazolopyridine inhibitors of myeloperoxidase | EPX, MPO, SERPINB1 | GRM2 3309/4885SLC9A1 1353/4885MPO 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.